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Enhancing the therapeutic efficacy of FTI tipifarnib in HRAS-mutant head and neck squamous cell 
carcinoma  
Head and neck squamous cell carcinoma (HNSCC) is a significant public health problem. RAS is a 
membrane-associated GTPase protein that is a well established driver for cancer progression. HRAS is 
the only oncoprotein whose signaling can be inhibited through delocalization by farnesyl transferase 
inhibitors (FTIs). One therapeutic inhibition of this RAS isoform is inhibiting the enzymes that target the 
RAS CAAX tetrapeptide motif in order to prevent membrane association. This inhibition is encouraging 
because HRAS requires membrane localization in order to perform critical biological processes. Recent 
clinical trials treating HRAS-mutant HNSCC with FTI tipifarnib have shown encouraging results, but 
there is room for improvement. A CRISPR screening was performed to identify targets that would 
sensitize HRAS mutant HNSCC to tipifarnib; the genetic screening identified regulators of the MAPK 
pathway as a sensitizer. We hypothesized that low doses of tipifarnib in combination with previously 
studied doses of ERK inhibitors would cause significant cell death and inhibit HRAS. I first evaluated the 
effect of a range of doses of tipifarnib by immunoblotting for the loss of HRAS through phase separation. 
I then evaluated apoptosis in HNSCC with the combination of tipifarnib and ERK inhibitors using flow 
cytometry. The results showed that some cell lines were more synergistic than others, but the combination 
treatment does enhance apoptosis and inhibit growth of HNSCC. Further studies are needed to evaluate 
why some cell lines are more synergistic than others.   
 
